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ABSTRACT  
 
The research has been conducted on the incident and analysis of risk factors 
drug liver injury (DILI) in a Surabaya Hospital. The aim of this study was to 
determine the incident of DILI, know which drugs cause DILI, and see the 
association of risk factors to DILI. The research method was descriptive and 
analytical observational (prospective cohort). Danan-Benichou scale is a tool 
used to ascertain drugs that cause DILI. Based on data collected for 3 
months, the population was 1202 patients. Samples fulfilling the inclusion 
and exclusion criteria were 310 patients, the risk drug group of DILI were 
285 patients (11 DILI, 274 Non-DILI), and the non-risk drug group 25 
patients (11 DILI, 14 Non-DILI). The incident of DILI was 3.55%. Drugs 
that cause DILI are ranitidine (4 cases), omeprazole (1 case), rifampicin (2 
cases), meropenem (1 case), ciprofloxacin (1 case), methotrexate (1 case), 
and dexamethasone (1 case). Characteristic of patients with DILI (11 
patients) are average age of 59.27 ± 15.54 years (23-73 years), belonging to 
high risk group (54.55%), male gender (81,82%), have moderate comorbid 
disease (54.55%), and are not comsumsing alcohol (100%). This research 
use logistic regression analysis through SPSS 17.0 program to see the 
relation of risk factor to DILI incident. The p results were obtained from sex 
(0,156), age (0,534), and comorbid 79isease (0,213)> α (0,05) which means 
gender, age, and comorbid disease do not significantly affect the incident of 
DILI. 
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ABSTRAK 
 
 Telah dilakukan penelitian terhadap angka kejadian dan analisis faktor risiko kerusakan hati yang 
disebabkan oleh obat (DILI) di sebuah Rumah Sakit Surabaya. Tujuan dari penelitian untuk mengetahui 
frekuensi kejadian DILI, obat-obat apa yang menyebabkan DILI dan melihat hubungan faktor risiko terhadap 
DILI. Metode penelitian adalah observasional deskriptif dan analitik (prospective cohort). Danan-Benichou 
scale merupakan alat bantu yang digunakan untuk memastikan obat penyebab kerusakan hati. Berdasarkan dari 
pengambilan data selama 3 bulan diperoleh populasi sebesar 1202 pasien. Sampel yang memenuhi kriteria 
inklusi dan eksklusi 310 pasien, kelompok obat berisiko 285 pasien (11 DILI, 274 Non-DILI), dan kelompok 
obat non-risiko 25 pasien (11 DILI, 14 Non-DILI). Frekuensi kejadian DILI adalah 3,55%. Obat yang 
menyebabkan kerusakan hati adalah ranitidine (4 kasus), omeprazole (1 kasus), rifampicin (2 kasus), meropenem 
(1 kasus), ciprofloxacin (1 kasus), methotrexate (1 kasus), dan dexamethasone (1 kasus). Pasien yang mengalami 
DILI karena obat berisiko (11 pasien) memiliki rata-rata usia 59,27 ± 15,54 tahun (23-73 tahun), tergolong 
dalam kelompok risiko tinggi (54,55%), jenis kelamin laki-laki (81,82%), pasien yang memiliki penyakit 
penyerta tingkat sedang (54,55%), dan tidak memiliki kebiasaan mengkonsumsi alkohol (100%). Untuk melihat 
hubungan faktor risiko terhadap kejadian DILI, dilakukan analisis menggunakan analisis regresi logistik melalui 
program SPSS 17.0, dan hasilnya diperoleh p dari jenis kelamin (0,156), usia (0,534), dan penyakit penyerta 
(0,213) > α (0,05), yang artinya jenis kelamin, usia, dan penyakit penyerta tidak signifikan berpengaruh terhadap 
kejadian DILI. 
 
Kata Kunci : Drug induced liver injury, DILI, faktor resiko 
 
INTRODUCTION 
Drug side effects are unexpected effects or unwanted 
effects, which occur in approproate drug use (Beard, 
2001). Drug side effects have major impact on public 
health and cause economic burdens, that cases can be 
prevented (Wu et al., 2010; Litaker & Wilson, 2005). 
In the United States, drug side effect is the top ten 
causes of death and spent 30 billion US dollars 
annually (Anderson & Borlak, 2011). In the United 
Kingdom, during period 1999-2008, 557.978 side 
effects are occured and increased risk of death (Wu et 
al., 2010). 
Drug induced disease is one of drug side effects form 
(Litaker & Wilson, 2005). Based on the results of 
preclinical and clinial trials, drug-induced liver injury 
(DILI) is the most common type of drug side effect. 
It is because liver is the metabolic center of drugs and 
xenobiotis, so liver is susceptible to toxicity (Bagheri 
et al., 2000; Holt & Ju, 2006). DILI is also influenced 
by many factors, such as genetics, age, gender, 
comorbid disease, alcohol, and nutritional status 
(Kaplowitz, 2004; MacLaren, 2005). 
About 20-30% of acute liver failure case had 90% 
mortality rate,  associated with drugs (Ward & Daly, 
2001). In 2003, National Institutes of Health (NIH) 
established the Drug-Induced Liver Injury Network 
(DILIN). DILIN is combination of 6 academic 
medical centers that identify and follow patient with 
idiosyncratic drug hepatotoxicity, and for the first 
time collect 300 cases of DILI in the United States. 
The agents of hepatotoxicity such as antibiotics 
(46%) and psychotropic drugs (15%) (Brett, 2009). 
About 800 drugs were associated with DILI events 
and caused hospital admissions 1 in 600 to 3500 
events (Ward & Daly, 2001). Increasing incident of 
DILI is due to the increasing number of chemical 
agents or drugs into the worldwide (MacLaren, 
2005). 
Clinical features of DILI are not specific. The 
reactions between each drug are different. Some are 
predictable and some are unpredictable. 
Unpredictable or idiosyncratic reactions often occur, 
and the rate is very high. These unpredictable events 
can be assessed and monitored through patient's 
history and laboratory results, such as Alanine 
Aminotranferase (ALT), Aspartate Aminotransferase 
(AST), Alkaline Phosphatase (ALP), Gamma-
Glutamyltransferase (GGT), 5'- Nucleotidase, Lactate 
Dehydrogenase (LDH), Total Bilirubin, Conjugated 
Bilirubin, and Unconjugated Bilirubin (Kaplowitz, 
2004; Kirchain & Rondal, 2008; Wells, Dipiro, 
Schwinghammer, & Dipiro, 2009). The  treatment 
history of patient is important for detecting DILI 
events (Wells, Dipiro, Schwinghammer, & Dipiro, 
2009). 
The instrument commonly used to assess DILI events 
is the CIOMS / RUCAM scale (Council for 
International Organizations of Medical 
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Sciences/Roussel Uclaf Causality Assessment 
Method). The CIOMS / RUCAM scale was proposed 
by Danan-Benichou at The International Consensus 
Meeting in the 1990s. Although the the 
CIOMS/RUCAM scale widely used in evaluating 
DILI, the criteria are very complex (Bagheri et al., 
2000; Lozano-lanagrán, Robles, Lucena, & Andrade, 
2011; Danan & Benichou, 1993; Andrade et al., 
2007; Wai, 2006). Therefore, in this study we used a 
simple scale measurementthat is Danan-Benichou 
scale (Wells, Dipiro, Schwinghammer, & Dipiro, 
2009). 
The research about incident of DILI in Indonesia is 
still less. For that purpose, this study was conducted 
to look how many DILI incident occurred in 
Indonesia. 
 
MATERIAL AND METHODS 
Sample 
This study population was inpatient in a Surabaya 
hospital. The study sample was study population with 
inclusion and exclusion criteria, which agreed to 
participate in this study. The samples collected was 
classified into 2 groups, the risk drug group and the 
non-risk drug group. Each of these groups was 
divided into 2 small groups, liver damage 
(DILI)group and non-DILI groups. The sampling of 
this quantitative research using the technique of non-
probability sampling, consecutive sampling. 
 
Inclusion and Exclusion Criteria 
Inclusion criteria, such as: 
a) Patients with age ≥ 18 years. 
b) Inpatient during this study period, with male and 
female sex that consuming drugs.  
c) Patients who have Liver Function Test (LFTs), 
such as ALT, AST, GGT, etc.  
Exclusion criteria, are patients with underlying liver 
disease, such as cirrhosis, viral hepatitis (A, B, C, D 
and E), autoimmune hepatitis, fatty liver, cancer with 
metastasis to the liver, DHF (Dengue High Fever), 
gall bladder obstruction, congestive heart failure 
(CHF), hypotension, hyperthermia, shock, vascular 
disease, biliary pancreatic tumors, bacterial sepsis, 
Salmonella infection, Cytomegalo virus (CMV), and 
Epstein-Barr virus (EBV). 
 
Research design 
The research is quantitative research, with descriptive 
and analytic observational (non-experimental) 
research method. 
Descriptive observational research method aims to 
see the frequency of liver damage events (percentage) 
induced by drugs and what drugs are dominant to 
cause liver damage. 
Analytic observational research method is 
prospective cohort study, aims to see the relationship 
of drugs to DILI events. The research design can be 
seen in the picture below. 
 
 
Figure 1. Research Design 
 
Research Instrument 
Danan-Benichou scale is the instrument to assess 
whether a drug causing liver damage (DILI).   
 
Data analysis 
Quantitative data analysis was analyzed by: 
Descriptive as percentage (%) of all DILI events 
      % 𝐷𝐼𝐿𝐼 𝑒𝑣𝑒𝑛𝑡𝑠 
=
𝑇𝑜𝑡𝑎𝑙 𝑜𝑓𝑡𝑕𝑒 𝑟𝑖𝑠𝑘 𝑑𝑟𝑢𝑔 𝑔𝑟𝑜𝑢𝑝 𝑤𝑖𝑡𝑕 𝐷𝐼𝐿𝐼
𝑡𝑜𝑡𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒            
𝑥 100% 
 
and statistical analysis, by multiple logistic regression 
method, aims to see the effect of risk factor on DILI. 
 
RESULTS AND DISCUSSION 
 
Percentage (%) of DILI and Non-DILI events  
Based on 3 months observations, the population of 
inpatients was 1202 patients, the sample was 310 
patients. The percentage of DILI and Non-DILI 
incident (%) can be seen in Table 1 and Figure 2. The 
incidence of liver damage (DILI) caused by the risk 
drug was 11 cases (3.55%). The incident of DILI is 
small, but should be monitored and avoided. 
 
Table 1. Percentage (%) Dili and Non-DILI incidents 
   Group DILI Non-DILI Total 
The Risk Drug 11  
(3,55%) 
274 
(88,39%) 
285 
(91,94%) 
Non-Risk Drug 11 
(3,55%) 
14 
(4,51%) 
25 
(8,06%) 
Total 22 
(7,1%) 
288 
(92,90%) 
310 
(100%) 
Population (Sample)
The Risk Drug 
Group
DILI
non-DILI
The Non-Risk 
Drug Group
DILI
non-DILI
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Figure 2. Graphs of DILI and Non-DILI Incidents 
 
Drug-induced hepatotoxicity is 3-10% of all side 
effects (Ward  & Daly, 2001). Another literature said 
7% of reported cases (Saukkonen et al., 2006). A 
French cohort study found that DILI incident 
occurred in 14 cases of 100,000 patients. Meanwhile, 
research in Spain, for approximately 10 years (since 
1990), occurred 461 cases of DILI. Research in 
Sweden from 1995-2005 reported 77 cases of DILI of 
1164 patients (6.6%) (Andrade et al., 2007; Polson, 
2007). Research in the UK reported 0.7 to 1.4% DILI 
cases (Andrade et al., 2007). A prospective study in 
Singapore for 1 year (2003-2004), reported 29 DILI 
cases (Lozano-lanagrán, Robles, Lucena, & Andrade, 
2011). Another study conducted in China 
(retrospectively) for 1 year reported 25 cases of DILI 
(Xu, Chen, Xu, & Zhou, 2012). 
 
Risk Drug Causing DILI 
 Eleven cases of DILI was found in this study 
(Fig. 3).There were 8 drugs causing DILI, including 
ranitidine (3 cases), omeprazole (1 case), 
methotrexate (1 case), meropenem (1 case), 
rifampicin (2 cases), ciprofloxacin (1 case), 
ceftriaxone (1 case), and dexamethasone (1 case). 
 
 
Figure 3. Risk Drug Causes DILI 
Each of these drugs can afford different forms of 
liver damagethat can be seen in the table 2. 
 
Table 2. Forms of liver damage caused by drugs 
suspected 
Drugs Liver Demage Form 
Ranitidine Hepatitis 
Ceftriaxone Hepatitis 
Meropenem Cholestasis 
Rifampicin Cholestasis 
Ciprofloxacin Cholestasis 
Omeprazole Hepatitis-Cholestasis (mixed) 
Methotrexate Cholestasis 
Dexamethasone Steatosis 
  
The eight drugs that cause liver damage are classified 
in a more specific group of class therapy. There are 4 
drugs belonging to the antibiotic group, namely 
meropenem, ciprofloxacin, ceftriaxone, and 
rifampicin. According to the literature, the large 
number of DILI cases resulting from antibiotic usage 
is 25-45% of all DILI cases (Colt & Shapiro, 1989). 
In this study, DILI cases resulting from antibiotic use 
(meropenem, ciprofloxacin, ceftriaxone, and 
rifampicin) were 5 cases (45.45%). The second 
highest frequency was occupied by antisecretory 
drugs (ranitidine and omeprazole) for 4 cases 
(36.36%), followed by antimetabolite (methotrexate) 
of 1 case (9.09%), and glucocorticoid 
(dexamethasone) of 1 case (9.09%). Antibiotics are 
the most common cause of DILI in this study. These 
results are similar in the United States, Europe, Japan 
and China, but are different from some Asian 
countries. 
 
A prospective study in the United States (5 locations) 
reported that drugs causing liver damage are 
antibiotics group (46%), followed by psychotropic 
drugs (15%), herbs (9%), immunomodulators (5.5%), 
analgesics (5%), antihypertensives (5%), endocrine 
agents (4%), and lipid-lowering agents (3.4%). Two 
other studies conducted in Europe reporting 
antibiotics, lipid-lowering agents, antidepressants, 
and analgesics are the main causes of DILI (Andrade 
et al., 2007). It was reported from a study in Spain, 
39% DILI cases occurred by antibiotics, 15% of 
central nervous system agents, 11% of analgesics and 
5% of lipid-lowering agents (Lozano-lanagrán, 
Robles, Lucena, & Andrade, 2011; Andrade et al., 
2007). A study in Switzerland (784 patients) 
mentioned that the main agents causing DILI were 
antibiotics (27%), analgesics (5%), dilsufiram 
0
20
40
60
80
100
DILI Non-DILI
3.55
88.39
3.55 4.51In
ci
d
en
ts
 (
%
)
Percentage (%) DILI and Non-DILI 
Incidents
The Risk
The Non-
Risk Drug
27.27%
9.09%
9.09%
9.09%
18.18%
9.09%
9.09%
9.09%
Risk Drug Causes DILI
Ranitidin 
Omeprazole
MTX 
Arrang et al./Jurnal Farmasi Galenika (Galenica Journal of Pharmacy) 2018; 4 (2): 79-86 
 
83 
(3.4%), carbamazepine (2.2%), and lipid-lowering 
agents (1 %). The result of retrospective studies in 
Japan (multicenter), the drugs that caused DILI were 
antibiotics (14%), then central nervous system drugs 
(10%), dietary supplements (10%), analgesics (9.9 
%), and Chinese herbs (7.1%) (Lozano-lanagrán, 
Robles, Lucena, & Andrade, 2011). Retrospective 
studies in China for 12 months (January-December 
2012), the drugs that cause DILI were antibiotics 
(32%) and glucocorticoids (24%) (Xu, Chen, Xu, & 
Zhou, 2012). However, different results were 
reported in Korea and Singapore. The prospective 
study in Korea reported the percentage of DILI 
incident due to herbs was 27.5%, drugs 20.8%, and 
dietary supplements 13.7%. For prospective study in 
Singapore of 29 DILI cases, traditional Chinese 
medicines (TCM) were the main cause of DILI 
incident (52%), followed by antituberculous drugs 
(24%) (Lozano-lanagrán, Robles, Lucena, & 
Andrade, 2011; Andrade et al., 2007). From these 
research reports, it can be concluded that antibiotics 
are the biggest cause of DILI in America, Europe, 
Japan and China, while for some Asian countries, 
TCM is the main cause of DILI incident. 
The assessment result through the Danan-Benichou 
scale instrument, risk value of each drug is 6-8. The 
meaning of the value is probable (50% -74%), that 
means there is considerable evidence and supports of 
the relationship between drug and DILI event. The 
results of the assessment are calculated without 
rechallenge assessment. If the rechallenge is 
performed, the likelihood of the assessment results 
may increase. 
 
Risk Factors of DILI incident 
Risk factors that may increase the risk of DILI are 
age, sex, genetics, duration of drug use, drug 
interactions, nutritional status, comorbid disease, and 
alcohol (Figure 4) (Maddrey, 2005; Sierra & Torres, 
2004). Risk factors in this study were confounding 
variables, including age, gender, nutritional status, 
comorbid disease, and alcohol. 
The risk factor of this research can be seen in table 3. 
The samples collected during the study (310 patients) 
are average of 57.94 ± 16.47 years (18-90 years), 
male sex (59.68%), all patients did not comsume 
alcohol (100%), and the patient did not have 
comorbid disease (41.61%). Nutritional status data in 
this study could not be collected for all samples, due 
to the limited available data related to nutritional 
status. Therefore, nutritional status data can not be 
presented and processed 
 
    Figure 4. Risk Factors of DILI (Sierra & Torres, 2004) 
 
Table 3. Data on risk factors for dili causes of overall 
sample research 
 
Patients with DILI (11 cases) had an average age of 
59.27 ± 15.54 years (23-73 years), high-risk age 
group (54.55%), male gender (81.82%), patients who 
had 2 comorbid disease (45.45%), and did not have a 
habit of consuming alcohol (100%). 
Comorbid disease in this study include Diabetes 
Mellitus (DM), Hypertension, HIV, Rheumatoid 
Arthritis (RA) or Osteoarthritis (OA), and Chronic 
Kidney Disease (CKD). Patient with DILI in this 
study had 2 comorbid disease. Most of the patients in 
this study had DM. Complications of type 2 diabetes 
is liver disorder and  associated with hepatobiliary 
disease, including non-alcoholic fatty liver disease, 
cirrhosis, acute liver failure, hepatocellular 
carcinoma, and cholelithiasis. The risk of liver 
damage due to methotrexate can be increased in DM 
patients (Ward & Daly, 2001; North-Lewis, 2008; 
Risk Factor Total Sample(%) 
Age Low Risk 
(<65 years) 
176 (56,77%) 
High Risk 
(≥65 years) 
134 (43,23%) 
Average±SD 57,94 ± 16,47  
(18-90 years) 
Gender Male 185 (59,68%) 
Famale 125 (40,32%) 
Comorbid 
disease 
0 129 (41,61%) 
1 87 (28,06%) 
2 69 (22,26%) 
3 25 (8,06%) 
4 0 
5 0 
Alcohol Yes 0 (0%) 
No 310 (100%) 
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Kaplowitz, 2007; Aithal, 2011; Metha, 2012). ALP 
increases also occur in patients with pulmonary 
infection (Fischbach & Dunning, 2009). In CKD 
patients, metabolites or substances that should be 
excreted through the kidneys, will reenter to the 
bloodstream, and consequently organs demage, 
including liver (North-Lewis, 2008). 
In this study, DILI occured at high risk age (≥ 65 
years), whereas Non-DILI was higher in low-risk 
patients (<65 years). Side effects occur in elderly 
patients is greater than young adults or children. 
Elderly patients decreased organ function, resulting 
in pharmacodynamic and pharmacokinetics changes 
from drugs (Ward & Daly, 2001; North-Lewis, 2008; 
Deleve, 2007; Kimmoun & Samuel, 2002). Drug 
interactions also occur in elderly patients. Decreased 
clearance of drug metabolites, drug bonds, hepatic 
blood flow, hepatic volume, and drug distributionwill 
affordingincreased plasma drug levels. Therefore, the 
risk of hepatotoxicity increases. Elderly patients 
usually have infections as well, less nutritional status, 
and multiple diseases. These may increase the risk of 
hepatotoxicity (Tostmann et al., 2008; Metha, 2012). 
A study had been reported that the greater incident of 
hepatotoxicity at age> 35 years than age <35 years 
(Saukkonen et al., 2006). Other literature reported 
DILI generally occur at age> 50 or 60 years, but not 
all studies showed similar results (Polson, 2007). 
From this study, DILI incidents were greater in men 
than in women. This may be due to the proportion of 
male and female samplesare not balance. The number 
of male patients was more than women. Women were 
more likely to take drugs.Their CYP3A enzyme 
activity was also greater than men, so women more 
often experienced DILI (1,5 times) than men (Ward 
& Daly, 2001; Tostmann et al., 2008; Deleve, 2007; 
Polson, 2007; Metha, 2012). Most studies have 
reported an increase in hepatotoxicity occurring in 
women, but not always in all drugs and all studies, 
even the results are not necessarily significant. 
Several cases reported DILI incident between men 
and women were more or less equal, and sometimes 
DILI incident was greater in males. A recent study in 
Sweden about risk factors and DILI incident, the 
results did not show differences of DILI incident 
between men and women (Saukkonen et al., 2006; 
Polson, 2007). Other studies have reported that 
women have hepatotoxicity  four times  more than 
men. Two other studies showed no increased risk of 
liver damage in women (Saukkonen et al., 2006). 
All patients in this study, both DILI and non-DILI 
events did not consume alcohol. If the patient 
consumes alcohol, the risk of DILI increases. The 
long-term use of alcohol induces the cytochrome 
P450 isoenzyme. It has potential to cause drug 
toxicity, such as methotrexate (Ward & Daly, 2001; 
North-Lewis, 2008; Tostmann et al., 2008; Deleve, 
2007; Aithal, 2011). Two mechanisms of alcohol 
cause hepatotoxicity. Firstly, cythochrome P450 
induced that increase the drugs metabolite. Secondly, 
it decreases liver gluthation that is necessary for the 
detoxification process of compounds (Kimmoun & 
Samuel, 2002). 
The influence of risk factor (confounding variable) to 
DILI event (dependent variable) was analyzed using 
logistic regression (multivariate analysis) through 
SPSS program version 17.0. The result of p value of 
sex (0,157), age (0,627), and comorbid disease 
(0,137) > α (0,05), which mean gender, age, and 
comorbid disease did not significantly influence the 
DILI incident (Table 4). 
 
Table 4. Relationship confounding variables to 
dependent variables 
Risk Factors p (sig.) 
Gender 0,157 
Age 0,627 
Comorbid disease 0,137 
  
The influence of risk factor on DILI incident, can be 
seen from Negelkerke R Square value, that is 6.8%. 
DILI incident is affected by risk factor of 6.8%. 
 
CONCLUSION 
The percentage of DILI incident in a Surabaya 
Hospital for 3 months was 3.55%. Drugs that causing 
DILI are antibiotics of 45,45% (meropenem 1 case, 
rifampicin 2 cases, ciprofloxacin 1 case, ceftriaxone 1 
case), antisecretory drugs of 36,36% (ranitidine 3 
cases, omeprazole 1 case), antimetabolite of 9,09% 
(methotrexate 1 case), and glucocorticoid 9.09% 
(dexamethasone 1 case). Risk factors such as age, 
sex, comorbid disease, and alcohol usage did not 
significantly affect the incident of DILI. 
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